Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

NCT07046221 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Esophagus Cancer

Interventions

DRUG: Tislelizumab
DRUG: Albumin-Bound Paclitaxel
DRUG: cis-platinum
PROCEDURE: Surgery
RADIATION: Radiation
DRUG: Nedaplatin
DRUG: Carboplatin

Sponsor

Fujian Cancer Hospital